Astra Zeneca AZ933QC0001 ADRIATIC
A Phase III randomized, double blind, placebo-controlled study of Durvalumab or Durvalumab and Tremelimumab as consolidation treatment for Stage I-III Limited Disease Small Cell Lung Cancer (SCLC) patients who have not progressed following concurrent chemoradiation therapy.
A Multicenter, Low-Interventional Study To Evaluate The Feasibility Of A Prospective Clinicogenomic Program
A phase 1b, 12-week, open-label study to assess the safety, Tolerability, pharmacokinetics and pharmacodynamics Following repeated subcutaneous administrations of PF-06946860 in patients with non small cell lung cancer and Cachexia
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Phase 3 Randomized, Open Label, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 510 Compared to Docetaxel in Subjects with Advanced/Metastatic NSCLC with KRAS p.G12C Mutation
Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the
Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects with Previously Treated Cancers
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.